Solid Biosciences Inc SLDB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLDB is a good fit for your portfolio.
News
-
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne
-
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
-
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
-
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
-
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
Solid Biosciences Gets Orphan Drug Designation for SGT-003
Trading Information
- Previous Close Price
- $9.99
- Day Range
- $9.01–9.89
- 52-Week Range
- $1.81–15.05
- Bid/Ask
- $7.00 / $10.18
- Market Cap
- $349.63 Mil
- Volume/Avg
- 143,309 / 270,431
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 88
- Website
- https://www.solidbio.com
Comparables
Valuation
|
Metric
|
SLDB
|
IMVT
|
RLYB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.49 | 6.05 | 0.59 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLDB
|
IMVT
|
RLYB
|
|---|---|---|---|
Quick Ratio | 8.52 | 21.56 | 11.87 |
Current Ratio | 8.94 | 22.14 | 12.39 |
Interest Coverage | — | — | — |
Quick Ratio
SLDB
IMVT
RLYB
Profitability
|
Metric
|
SLDB
|
IMVT
|
RLYB
|
|---|---|---|---|
Return on Assets (Normalized) | −42.17% | −43.33% | −43.05% |
Return on Equity (Normalized) | −53.06% | −47.83% | −45.88% |
Return on Invested Capital (Normalized) | −49.24% | −52.69% | −50.14% |
Return on Assets
SLDB
IMVT
RLYB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wthrjndzs | Nhp | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vswkxxs | Sfmwmw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qrrldppj | Wlqnfp | $98.1 Bil | |
MRNA
| Moderna Inc | Qfzcdpnn | Vdkrx | $39.1 Bil | |
ARGX
| argenx SE ADR | Zrtwppkrc | Gbgw | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vdnlmzz | Jjmkp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lgjcvfkm | Tyrnbqm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jjzbghdc | Qtytwgb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zgycszqsv | Mpbjyh | $12.5 Bil | |
INCY
| Incyte Corp | Gswqgnhj | Pplbtxb | $11.9 Bil |